Androgel Manufacturers Sued in Class Action for Antitrust Violations
Posted on: Tuesday, 7 April 2009, 12:44 CDT
Androgel is a testosterone replacement therapy for men who have a deficiency or absence of endogenous testosterone.
The lawsuit is a class action filed on behalf of all persons or entities that purchased Androgel directly from any defendant from at least
The suit alleges that the brand name and generic manufacturers conspired to fix and raise the price of Androgel, by overcharging Plaintiffs and others by millions of dollars and depriving them of cheaper generic versions of the drug. The complaint estimates that hundreds or thousands of people or companies have been economically injured by the drug manufacturers' conduct.
Two law firms have joined forces to litigate the class action: RodaNast, P.C. in
SOURCE RodaNast, P.C.
Source: PR Newswire
Related Articles
- Spectrum Pharmaceuticals Announces Sale of Injectable Generic Drugs to Sagent Pharmaceuticals, Inc.
- Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry Report Now Available
- In The Generic Drug Manufacturing Environment the Pace of Corporate Consolidation Grows Ever Faster As Eight Significant Acquisitions Were Announced In 2006
- GPhA Hails Senate Agricultural Appropriations Subcommittee Proposal for $10 Million Increase in Funding for FDA Office of Generic Drugs
- Mason Law Firm Files First Class Action Against Sprint for Violation of Privacy Laws
- Generic Drug Payoff Draws Gov't. Interest
- KV Pharmaceutical in Generic Drug Deal With Gedeon
- KV Pharmaceutical Company to Market New Generic Drugs in U.S. Via Exclusive Deal With Gedeon Richter
- Free-for-All Over Generic Drugs in Europe Bitter Pills / Why Europeans Pay What They Pay
- Teva Acquiring Ivax Corp. For $7.4B; Merger Will Create Biggest Maker of Generic Drugs
 |
 |
User Comments (0)
RSS Feeds